TrialPloS one2016

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.

Emilia Quattrocchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.